Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on INT 1. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN116924866A reveals a green photocatalytic method for internal alkyne synthesis, offering cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel sulfur-mediated synthesis offers cost-effective, metal-free production of high-purity triazole intermediates for pharmaceutical applications and global supply chains.
Discover a metal-free, low-cost synthesis method for 5-trifluoromethyl-1,2,4-triazole compounds. Eliminate heavy metal catalysts and reduce supply chain risks for your API manufacturing.
Solve low-yield C-H activation challenges with 94% yield & 92% ee. Scale to 100MT/yr with no byproducts. Contact for COA/MSDS.
Eliminate heavy metal catalysts and complex steps in 1,2,4-triazole synthesis. Our CDMO expertise ensures scalable production of high-purity intermediates for drug development.
Solve high-cost, low-yield issues in minodronic acid synthesis. New halogenation-Grignard method offers 83-88% yield, no toxic reagents, and scalable production for osteoporosis drugs.
Discover how novel nintedanib synthesis routes with 92% yield and mild conditions reduce production costs by 30% while ensuring GMP compliance for IPF treatment.
Solve toxic reagent risks in phenanthridinone production. Discover 1 atm CO pressure process for high-yield, scalable API intermediates with reduced supply chain risks.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Discover a cost-efficient, scalable synthesis method for furo[3,2-b]pyridine derivatives, eliminating precious metal use and reducing production costs for JAK1 inhibitor development.
Solve high-cost, multi-step synthesis of Vibegron intermediates. New phosphine-free route reduces waste, improves yield, and ensures supply chain stability for OAB drug production.
Solve high-cost synthesis challenges for 5-trifluoromethyl-1,2,4-triazole compounds. Our metal-free, scalable method reduces catalyst costs and supply chain risks for GlyT1 inhibitors.
Solve high-cost montelukast synthesis with this 5-step method. Achieve 89% yield, eliminate expensive reagents, and ensure GMP-compliant scale-up. Contact for custom synthesis.
Solve low-yield & heavy metal issues in pyrido[1,2-a][1,3,5]-triazin-4-one synthesis. Scale to 100MT/yr with anhydrous-free, cost-effective CDMO solutions.
Solve bempedoic acid synthesis challenges with trityl-protected intermediate. 97.8% yield, no toxic reagents, scalable for GMP production.
Solve low yield and toxic reagent issues in zafirlukast intermediate production. 91.6% yield, eco-friendly process, and scalable CDMO solutions for pharma R&D and procurement.
Discover a novel metal-free synthesis for pyrido[1,2-a][1,3,5]-triazin-4-one that eliminates heavy metal waste, reduces production costs, and streamlines your supply chain for pharmaceutical intermediates.
Solve high cost & safety risks in Baloxavir production. New route avoids chiral resolution, 98.7% ee, 84.5% yield. Scale to 100 MT/yr.
Discover how nickel/photo-redox catalysis enables 78-83% yield in C-H cross-coupling for pharmaceutical intermediates with 99:1 regioselectivity. Reduce production costs and supply chain risks.
Discover a cost-effective, metal-free synthesis method for 5-trifluoromethyl-1,2,4-triazole compounds. Eliminate heavy metal catalysts and simplify supply chain for pharmaceutical intermediates.